Pfizer and its German partner, BioNTech, said Monday that an early analysis showed their three-dose coronavirus vaccine regimen triggered a strong immune response in young children, proving 80 percent effective at preventing symptomatic infections in children 6 months to 4 years old.
The results, along with other recent developments, signal that the long and frustrating wait for a vaccine for the youngest children, the last group to lack access, could be over within weeks.
A few hours after Pfizer and BioNTech issued a news release announcing the data, which has not been peer reviewed, the Food and Drug Administration (FDA) said its outside experts will meet June 14 and 15 to discuss the Moderna and Pfizer-BioNTech pediatric vaccines. Pfizer and BioNTech said they plan to finish filing data with the FDA this week — and warned that the efficacy number was fluid because results are still arriving.
Please select this link to read the complete article from The Washington Post.